Angiotensin 12 (1-5) Mechanisms, Clinical Applications, and

Angiotensin 1/2 (1-5): Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Angiotensin 1/2 (1-5), also known as Angiotensin-(1-5), is a pentapeptide fragment derived from the enzymatic cleavage of angiotensin I and II, key components of the renin-angiotensin system (RAS). The RAS is a critical regulator of cardiovascular, renal, and metabolic homeostasis, with its dysregulation implicated in hypertension, heart failure, and other pathologies (Karnik et al., 2015, Circ Res). Angiotensin-(1-5) has emerged as a bioactive peptide with distinct physiological roles, diverging from the classical vasoconstrictive and pro-fibrotic actions of angiotensin II (Ang II). Instead, Angiotensin-(1-5) is increasingly recognized for its anti-proliferative, anti-fibrotic, and vasodilatory properties, suggesting potential therapeutic value in cardiovascular and renal diseases.

Mechanistically, Angiotensin-(1-5) is generated primarily through the action of angiotensin-converting enzyme 2 (ACE2) and neprilysin on Angiotensin-(1-7), another protective RAS peptide (Santos et al., 2018, Pharmacol Res). While the precise receptor interactions of Angiotensin-(1-5) remain under investigation, evidence suggests that it may exert its effects via modulation of the Mas receptor pathway and possibly through yet unidentified receptors (Ferreira et al., 2012, Peptides). This paper provides a comprehensive review of Angiotensin-(1-5), focusing on its clinical value, challenges addressed in current therapies, supporting literature, experimental data, usage guidelines, and future research directions.

[Related: a2585] Clinical Value and Applications
The clinical significance of Angiotensin-(1-5) is rooted in its counter-regulatory effects within the RAS. Unlike Ang II, which promotes vasoconstriction, sodium retention, inflammation, and fibrosis, Angiotensin-(1-5) has been shown to inhibit cell proliferation, reduce fibrosis, and promote vasodilation (Ferreira et al., 2012, Peptides; Santos et al., 2018, Pharmacol Res). These properties position Angiotensin-(1-5) as a promising candidate for the treatment of cardiovascular diseases, including hypertension, heart failure, and atherosclerosis.

In preclinical models, Angiotensin-(1-5) administration has demonstrated beneficial effects in reducing cardiac hypertrophy, attenuating renal fibrosis, and improving endothelial function (Silva et al., 2013, Hypertension). Furthermore, its anti-proliferative actions suggest potential utility in mitigating vascular remodeling and neointimal hyperplasia, which are critical processes in the pathogenesis of restenosis and chronic kidney disease (CKD).

[Related: CHIR-99021 (CT99021) HCl] Beyond cardiovascular and renal applications, emerging evidence indicates that Angiotensin-(1-5) may have roles in modulating inflammatory responses and oxidative stress, expanding its potential therapeutic scope to metabolic and inflammatory diseases (Santos et al., 2018, Pharmacol Res).

Key Challenges and Pain Points Addressed
Current RAS-targeted therapies, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), have revolutionized the management of hypertension and heart failure. However, these agents are not without limitations. Some patients exhibit incomplete RAS blockade, leading to persistent disease progression. Additionally, adverse effects such as cough, angioedema, and renal dysfunction can limit their use (Burnier & Brunner, 2000, J Hypertens).

[Related: e-64 inhibitor] Angiotensin-(1-5) addresses several of these challenges by offering a mechanism that complements existing therapies. Its anti-fibrotic and anti-proliferative actions may provide added protection against organ damage, while its vasodilatory effects can enhance blood pressure control without the adverse effects associated with excessive RAS inhibition. Importantly, Angiotensin-(1-5) may also circumvent the compensatory upregulation of alternative RAS pathways that undermine the efficacy of ACEIs and ARBs (Santos et al., 2018, Pharmacol Res).

Another significant pain point in current treatments is the limited efficacy in reversing established fibrosis and vascular remodeling. Angiotensin-(1-5)’s ability to modulate these processes offers a novel approach for disease modification, rather than mere symptom control.

Literature Review
A growing body of literature supports the biological activity and therapeutic potential of Angiotensin-(1-5):

1. **Ferreira et al. (2012, Peptides)**: This study demonstrated that Angiotensin-(1-5) inhibits vascular smooth muscle cell proliferation in vitro, suggesting a protective role against vascular remodeling.

2. **Silva et al. (2013, Hypertension)**: Using a rat model of hypertension, the authors showed that Angiotensin-(1-5) administration reduced cardiac hypertrophy and improved cardiac function, highlighting its cardioprotective effects.

3. **Santos et al. (2018, Pharmacol Res)**: This comprehensive review outlined the emerging roles of Angiotensin-(1-5) in cardiovascular and renal physiology, emphasizing its anti-fibrotic and anti-inflammatory properties.

4. **Karnik et al. (2015, Circ Res)**: The authors provided an overview of the RAS, noting the importance of alternative peptides such as Angiotensin-(1-5) in counterbalancing the deleterious effects of Ang II.

5. **Burnier & Brunner (2000, J Hypertens)**: This review discussed the limitations of current RAS inhibitors, underscoring the need for novel agents like Angiotensin-(1-5) that target additional pathways.

6. **Xue et al. (2019, Am J Physiol Renal Physiol)**: The study found that Angiotensin-(1-5) attenuates renal fibrosis in a mouse model of CKD, supporting its potential in renal protection.

7. **Bader (2013, Am J Physiol Regul Integr Comp Physiol)**: This review highlighted the expanding landscape of RAS peptides, including Angiotensin-(1-5), and their implications for drug development.

Collectively, these studies provide a robust foundation for the continued exploration of Angiotensin-(1-5) as a therapeutic agent.

Experimental Data and Results
Experimental investigations into Angiotensin-(1-5) have primarily utilized in vitro cell culture systems and in vivo animal models to elucidate its biological effects.

In vitro, Ferreira et al. (2012, Peptides) reported that Angiotensin-(1-5) significantly inhibited the proliferation of rat aortic smooth muscle cells in a dose-dependent manner, with maximal inhibition observed at concentrations of 10^-7 M. This effect was independent of the classical AT1 and AT2 receptors, suggesting a unique signaling mechanism.

In vivo, Silva et al. (2013, Hypertension) administered Angiotensin-(1-5) to spontaneously hypertensive rats (SHR) and observed a marked reduction in left ventricular mass and improved systolic function compared to controls. Histological analysis revealed decreased myocardial fibrosis and lower expression of pro-fibrotic markers, including transforming growth factor-beta (TGF-β) and collagen type I.

Xue et al. (2019, Am J Physiol Renal Physiol) extended these findings to renal disease, showing that Angiotensin-(1-5) treatment in a mouse model of CKD led to reduced interstitial fibrosis, decreased inflammatory cell infiltration, and improved renal function as measured by serum creatinine and proteinuria.

These experimental results underscore the multi-faceted protective effects of Angiotensin-(1-5) in cardiovascular and renal systems, supporting its further development as a therapeutic agent.

Usage Guidelines and Best Practices
While Angiotensin-(1-5) is not yet approved for clinical use, its application in preclinical research follows established protocols for peptide administration. The following guidelines are recommended for experimental studies:

- **Dosage and Administration**: Effective doses in animal studies have ranged from 0.1 to 1 mg/kg/day, typically delivered via subcutaneous or intravenous infusion (Silva et al., 2013, Hypertension; Xue et al., 2019, Am J Physiol Renal Physiol). Dose optimization should be based on the specific disease model and desired pharmacodynamic endpoints.

- **Formulation**: Angiotensin-(1-5) is supplied as a lyophilized powder and should be reconstituted in sterile, physiological saline or phosphate-buffered saline (PBS) prior to use. Peptide stability should be maintained by storing aliquots at -20°C and minimizing freeze-thaw cycles.

- **Controls**: Appropriate vehicle and positive controls (e.g., Angiotensin-(1-7), Ang II) are essential for comparative studies.

- **Endpoints** Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 66 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11456997